Market capitalization | $170.60m |
Enterprise Value | $160.06m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 6.76 |
EV/Sales (TTM) EV/Sales | 3.24 |
P/S ratio (TTM) P/S ratio | 3.46 |
P/B ratio (TTM) P/B ratio | negative |
Revenue growth (TTM) Revenue growth | 278.09% |
Revenue (TTM) Revenue | $49.35m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
5 Analysts have issued a Fennec Pharmaceuticals Inc. forecast:
5 Analysts have issued a Fennec Pharmaceuticals Inc. forecast:
Sep '24 |
+/-
%
|
||
Revenue | 49 49 |
278%
278%
|
|
Gross Profit | 46 46 |
272%
272%
|
|
EBITDA | 1.68 1.68 |
110%
110%
|
EBIT (Operating Income) EBIT | 1.68 1.68 |
110%
110%
|
Net Profit | -1.13 -1.13 |
94%
94%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Fennec Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in the development of sodium thiosulfate for the prevention of ototoxicity from cisplatin in pediatric cancer patients. The company was founded by Orest W. Blaschuk on September 3, 1996 and is headquartered in Durham, NC.
Head office | Canada |
CEO | Jeffrey Hackman |
Employees | 29 |
Founded | 1996 |
Website | www.fennecpharma.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.